China-based Sinovac Biotech (Nasdaq: SVA), which earlier this week revealed a takeover approach from SAIF Partners, today announced that it has received an alternative offer to acquire the company.
Sinovac’s board of directs on February 4, received a preliminary non-binding proposal letter, dated February 3, 2016, from a consortium comprised of PKU V-Ming (Shanghai) Investment Holdings, Shandong Sinobioway Biomedicine, CICC Qianhai Development (Shenzhen) Fund Management, Beijing Sinobioway Group, Heng Feng Investments (International) Limited and Fuerde Global Investment Limited, to acquire all of the outstanding common shares of the company for $7.00 in cash per common share. This compares with the previous offer of $6.18 per share, news of which pushed Sinovac’s stock price up 18% to $5.94. The stock rose a further 6.38% to $6.17 in pre-market trading on the Nasdaq this morning.
Sinovac’s special committee of independent directors, which was formed to consider the preliminary non-binding proposal letter, dated January 30, 2016, from Weidong Yin, chairman, president and chief executive of the company, and SAIF Partners and/or its affiliates will carefully consider and evaluate both proposals with the assistance of the special committee's independent financial and legal advisors to be appointed in due course.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze